Eli Lilly: Covid-19 drug starts Phase III trial
(CercleFinance.com) - Eli Lilly today reports the start of a phase III trial evaluating LY-CoV555 for the prevention of infection by SARS-CoV-2 and Covid-19 for residents and staff at long-term care institutions.
This study, called Blaze-2 is set to recruit 2,400 people and assess whether a single dose of LY-CoV555 reduces the infection rate within four weeks, and Covid-19 complications within eight weeks.
More than 40% of coronavirus deaths in the United States are linked to long-term care facilities, Eli Lilly noted, which therefore points out an urgent need for therapeutic strategies to prevent Covid-19 in this vulnerable population.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
This study, called Blaze-2 is set to recruit 2,400 people and assess whether a single dose of LY-CoV555 reduces the infection rate within four weeks, and Covid-19 complications within eight weeks.
More than 40% of coronavirus deaths in the United States are linked to long-term care facilities, Eli Lilly noted, which therefore points out an urgent need for therapeutic strategies to prevent Covid-19 in this vulnerable population.
Copyright (c) 2020 CercleFinance.com. All rights reserved.